J.B. Chemicals & Pharmaceuticals Limited , a Torrent Group Company, has filed a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the National Stock Exchange of India Limited about newspaper advertisements published on May 11, 2026. These advertisements pertain to the Notice of Hearing of Petition in the matter of the proposed Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders. The advertisements were published in Indian Express (English) — all India Editions — and in Sandesh, Divya Bhaskar, and Gujarat Samachar (Gujarati) — all Gujarat Editions.

Scheme of Amalgamation: Key Details

The proposed transaction involves the amalgamation of J.B. Chemicals & Pharmaceuticals Limited (Petitioner Transferor Company/JB Pharma) with Torrent Pharmaceuticals Limited (Petitioner Transferee Company/Torrent Pharma) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The key procedural milestones and details of the scheme are summarised below:

NCLT Hearing and Participation Process

The Company Petition under Sections 230 and 232 of the Companies Act, 2013, was presented by the petitioner companies on April 29, 2026, and was admitted by the Hon'ble National Company Law Tribunal, Ahmedabad Bench on May 7, 2026. Pursuant to the order dated May 7, 2026, the petition has been fixed for hearing before the Hon'ble Tribunal on Thursday, June 11, 2026.

Any person wishing to support or oppose the Company Petition at the hearing is required to:

• Submit an affidavit with the grounds of support or opposition in the form of a representation before the Hon'ble Tribunal
• Provide a written copy to the Petitioner Companies' Advocate, Swati Soparkar, at 301, Shivalik-10, Opp. SBI Zonal Office, Near Old Excise Chowky, S.M. Road, Ambavadi, Ahmedabad – 380015, and/or at swati.soparkar@gmail.com
• Send a copy to Mr. Sandeep Phadnis, Company Secretary & Compliance Officer of the Petitioner Transferor Company, at Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400030, and/or at investorrelations@jbpharma.com
• Send a copy to Mr. Chintan Trivedi, Company Secretary & Compliance Officer of the Petitioner Transferee Company, at Avirat, Thaltej Shilaj Road, Ahmedabad – 380059, Gujarat, India, and/or at investorservices@torrentpharma.com
• Ensure all documents are received at least two days before the date fixed for the hearing
• Appear in person or through an advocate at the hearing

A copy of the Company Petition will be made available to any person requiring the same upon payment of the prescribed charges.

Regulatory Disclosure

The disclosure was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary of J.B. Chemicals & Pharmaceuticals Limited, on May 11, 2026. The registered office of J.B. Chemicals & Pharmaceuticals Limited is located at 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS, Satellite, Ahmedabad – 380015, Gujarat, India, while its corporate office is at Cnergy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400025.

J b chemicals and pharmaceuticals Limited has executed another significant block trade on the National Stock Exchange (NSE), marking continued institutional transaction activity in the pharmaceutical sector.

Latest Block Trade Details

The company completed a substantial block trade with the following specifications:

Transaction Significance

Block trades represent large-volume transactions typically executed by institutional investors, mutual funds, or other significant market participants. These transactions are conducted outside the regular market mechanism to minimize price impact on the stock. The execution of such a substantial trade indicates active institutional interest in the pharmaceutical company's shares.

The price point of ₹2006.70 per share reflects the current market valuation at which institutional investors are willing to transact in J.B. Chemicals & Pharmaceuticals shares. Such transactions often provide insights into institutional sentiment and can influence market perception of the company's prospects.

Market Activity Pattern

This latest transaction follows previous institutional activity in the stock, demonstrating sustained interest from large investors in the pharmaceutical sector. The consistent pricing levels around the ₹2006-2007 range suggest stable institutional demand at current market valuations.